Covovax, Novavax-developed vaccine, is available in Q3 2021

by The Manila Times

Jul 01, 2021 6:30 pm

A vaccine with an overall efficacy rate of 90.4 percent and a 93.2 percent efficacy against variants of interest and concern, developed by US biotechnology company Novavax, is expected to arrive in the country in the third quarter of the year. The vaccine's trade name in the Philippines is Covovax.

This was announced by Faberco Life Sciences Inc., the local pharmaceutical firm that has secured the distribution rights to the vaccine in the Philippines.

Already have an active account? Log in here to continue reading.
Or
Subscribe to the Premium Subscription plan to access this subscriber-exclusive article.

Related Articles

Natura &Co shows improved revenue trends, with strong performance by Natura in Brazil and signs of stability at Avon in the country

Helzberg Diamonds and Proximity join forces to elevate customer experience

UNESCO Intangible Cultural Heritage "Bunraku" on World Stage: Japan's National Theatre to Present Spectacular Fusion of Tradition and Anime in United States

AdvoLogix Announces: AI-Enhanced Matter Financial Management for Law Firms

NFP Acquires Orca Financial Group, a Specialist Financial Brokerage

rabbit r1, the Consumer AI-native Pocket Companion, Expands Availability Across the UK and European Union

Infortrend U.2 NVMe Storage Empowers Airport AI for Faster Passenger Processing